184 related articles for article (PubMed ID: 36646020)
1. The effects of cannabidiol and Δ9-tetrahydrocannabinol, alone and in combination, in the maximal electroshock seizure model.
Dlugosz L; Zhou HZ; Scott BW; Burnham M
Epilepsy Res; 2023 Feb; 190():107087. PubMed ID: 36646020
[TBL] [Abstract][Full Text] [Related]
2. Antiseizure effects of the cannabinoids in the amygdala-kindling model.
Fallah MS; Dlugosz L; Scott BW; Thompson MD; Burnham WM
Epilepsia; 2021 Sep; 62(9):2274-2282. PubMed ID: 34251027
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Cannabidiol in Animal Seizure Models by the Epilepsy Therapy Screening Program (ETSP).
Klein BD; Jacobson CA; Metcalf CS; Smith MD; Wilcox KS; Hampson AJ; Kehne JH
Neurochem Res; 2017 Jul; 42(7):1939-1948. PubMed ID: 28478594
[TBL] [Abstract][Full Text] [Related]
4. Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models.
Patra PH; Barker-Haliski M; White HS; Whalley BJ; Glyn S; Sandhu H; Jones N; Bazelot M; Williams CM; McNeish AJ
Epilepsia; 2019 Feb; 60(2):303-314. PubMed ID: 30588604
[TBL] [Abstract][Full Text] [Related]
5. Effects of cannabidiol and Δ9-tetrahydrocannabinol in the elevated plus maze in mice.
Liu J; Scott BW; Burnham WM
Behav Pharmacol; 2022 Apr; 33(2&3):206-212. PubMed ID: 33883447
[TBL] [Abstract][Full Text] [Related]
6. Cannabidiol Exerts Anticonvulsant Effects Alone and in Combination with Δ
Javadzadeh Y; Santos A; Aquilino MS; Mylvaganam S; Urban K; Carlen PL
Cells; 2024 Mar; 13(6):. PubMed ID: 38534310
[TBL] [Abstract][Full Text] [Related]
7. Interactions between cannabidiol and Δ
Anderson LL; Low IK; McGregor IS; Arnold JC
Br J Pharmacol; 2020 Sep; 177(18):4261-4274. PubMed ID: 32608111
[TBL] [Abstract][Full Text] [Related]
8. Cannabis, cannabidiol, and epilepsy--from receptors to clinical response.
Szaflarski JP; Bebin EM
Epilepsy Behav; 2014 Dec; 41():277-82. PubMed ID: 25282526
[TBL] [Abstract][Full Text] [Related]
9. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
10. Cannabis constituents reduce seizure behavior in chemically-induced and scn1a-mutant zebrafish.
Thornton C; Dickson KE; Carty DR; Ashpole NM; Willett KL
Epilepsy Behav; 2020 Sep; 110():107152. PubMed ID: 32585475
[TBL] [Abstract][Full Text] [Related]
11. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
[TBL] [Abstract][Full Text] [Related]
12. Cannabidiol, but Not Δ9-Tetrahydrocannabinol, Has Strain- and Genotype-Specific Effects in Models of Psychosis.
Mielnik CA; Li CK; Ramsey AJ; Salahpour A; Burnham WM; Ross RA
Cannabis Cannabinoid Res; 2024 Feb; 9(1):174-187. PubMed ID: 36251462
[No Abstract] [Full Text] [Related]
13. Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats.
Parker LA; Burton P; Sorge RE; Yakiwchuk C; Mechoulam R
Psychopharmacology (Berl); 2004 Sep; 175(3):360-6. PubMed ID: 15138755
[TBL] [Abstract][Full Text] [Related]
14. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.
Hindocha C; Freeman TP; Schafer G; Gardener C; Das RK; Morgan CJ; Curran HV
Eur Neuropsychopharmacol; 2015 Mar; 25(3):325-34. PubMed ID: 25534187
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of the FDA-approved cannabidiol on the development and persistence of temporal lobe epilepsy and complex focal onset seizures.
Reddy DS; Mbilinyi RH; Ramakrishnan S
Exp Neurol; 2023 Jan; 359():114240. PubMed ID: 36216124
[TBL] [Abstract][Full Text] [Related]
16. Single and combined effects of Δ
King KM; Myers AM; Soroka-Monzo AJ; Tuma RF; Tallarida RJ; Walker EA; Ward SJ
Br J Pharmacol; 2017 Sep; 174(17):2832-2841. PubMed ID: 28548225
[TBL] [Abstract][Full Text] [Related]
17. Cannabis constituent synergy in a mouse neuropathic pain model.
Casey SL; Atwal N; Vaughan CW
Pain; 2017 Dec; 158(12):2452-2460. PubMed ID: 28885457
[TBL] [Abstract][Full Text] [Related]
18. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG
JAMA; 2020 Dec; 324(21):2177-2186. PubMed ID: 33258890
[TBL] [Abstract][Full Text] [Related]
19. Potential Benefit of Add-on Δ9-Tetrahydrocannabinol in Pediatric Drug-Resistant Epilepsy: A Case Series.
Nowicki M; Bourgeois-Tardif S; Diaz PL; Hebert FO; Sanon NT; Champagne PO; Major P; Sell E; Bitton J; Lewis E; Weil AG
Can J Neurol Sci; 2022 Jul; 49(4):595-597. PubMed ID: 34183079
[TBL] [Abstract][Full Text] [Related]
20. Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol.
Vann RE; Gamage TF; Warner JA; Marshall EM; Taylor NL; Martin BR; Wiley JL
Drug Alcohol Depend; 2008 Apr; 94(1-3):191-8. PubMed ID: 18206320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
